NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers

Cancer Cell. 2013 Jan 14;23(1):48-62. doi: 10.1016/j.ccr.2012.12.001.

Abstract

Using sequential gene expression profiling (GEP) samples, we defined a major functional group related to drug resistance that contains chromosomal instability (CIN) genes. One CIN gene in particular, NEK2, was highly correlated with drug resistance, rapid relapse, and poor outcome in multiple cancers. Overexpressing NEK2 in cancer cells resulted in enhanced CIN, cell proliferation and drug resistance, while targeting NEK2 by NEK2 shRNA overcame cancer cell drug resistance and induced apoptosis in vitro and in a xenograft myeloma mouse model. High expression of NEK2 induced drug resistance mainly through activation of the efflux pumps. Thus, NEK2 represents a strong predictor for drug resistance and poor prognosis in cancer and could be an important target for cancer therapy.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / metabolism
  • Antineoplastic Agents / therapeutic use*
  • Cell Proliferation
  • Chromosomal Instability / genetics
  • Drug Resistance, Neoplasm / genetics*
  • Female
  • Gene Expression Profiling
  • Humans
  • Male
  • Mice
  • Multiple Myeloma / diagnosis
  • Multiple Myeloma / drug therapy
  • Multiple Myeloma / genetics*
  • NIMA-Related Kinases
  • Prognosis
  • Protein Serine-Threonine Kinases / antagonists & inhibitors
  • Protein Serine-Threonine Kinases / genetics*
  • RNA Interference

Substances

  • Antineoplastic Agents
  • NEK2 protein, human
  • NIMA-Related Kinases
  • Protein Serine-Threonine Kinases

Associated data

  • GEO/GSE19554